Oncology ESMO25: The changing landscape of rare oncology, with Jan Ki... ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.